Published in Rheumatology (Oxford) on June 01, 2001
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol (2011) 1.70
Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 (2007) 1.44
Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6. J Autoimmun (2012) 1.43
Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am (2010) 1.38
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int (2011) 1.17
Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms. Acta Biomater (2013) 1.15
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int (2005) 1.11
Scaffold design for bone regeneration. J Nanosci Nanotechnol (2014) 1.06
Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther (2002) 1.06
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis (2003) 1.06
Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther (2004) 0.99
Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis (2002) 0.99
Relationship between serum RANKL and RANKL in bone. Osteoporos Int (2011) 0.94
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis Res Ther (2007) 0.92
Inflammatory response in patients with active and inactive osteoarthritis. Rheumatol Int (2009) 0.90
The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther (2012) 0.88
Rheumatoid arthritis and the role of oral bacteria. J Oral Microbiol (2010) 0.87
Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab (2011) 0.87
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 0.86
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther (2008) 0.84
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther (2012) 0.84
Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology (2008) 0.83
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. Rheumatol Int (2007) 0.81
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int (2007) 0.81
Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int (2011) 0.81
Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) (2015) 0.78
Regulation of bone lysis in inflammatory diseases. Inflammopharmacology (2003) 0.77
CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis. Arthritis Res Ther (2015) 0.76
An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases. Wien Med Wochenschr (2010) 0.76
HDL-Associated Paraoxonase 1 as a Bridge between Postmenopausal Osteoporosis and Cardiovascular Disease. Chonnam Med J (2014) 0.76
Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis. Sci Rep (2016) 0.75
RANKL, OPG and CTR mRNA expression in the temporomandibular joint in rheumatoid arthritis. Exp Ther Med (2015) 0.75
Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts. PLoS One (2016) 0.75
Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS One (2016) 0.75
Increased risk of vertebral fracture in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore) (2016) 0.75
The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clin Cases Miner Bone Metab (2007) 0.75
The role of stromal cells in inflammatory bone loss. Clin Exp Immunol (2017) 0.75
Efficacy of radiosynoviorthesis and its impact on chosen inflammatory markers. Rheumatol Int (2011) 0.75
OsteoRheumatology: a new discipline? RMD Open (2015) 0.75
Expression of the receptor activator of nuclear factor-kB ligand in peripheral blood mononuclear cells in patients with acute Charcot neuroarthropathy. Int J Med Sci (2016) 0.75
Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) (1993) 2.20
Synthetic bone graft substitutes. ANZ J Surg (2001) 1.84
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) (2003) 1.83
Insulin receptor expression in primary and cultured osteoclast-like cells. Bone (1998) 1.68
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Anatomical reduction of intra-articular fractures of the distal radius. An arthroscopically-assisted approach. J Bone Joint Surg Br (2000) 1.55
Department of Biological Sciences, University of Warwick, Coventry, CV47AL, England. J Gen Virol (1974) 1.49
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int (2008) 1.39
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol (2005) 1.27
Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. Cancer Res (1980) 1.24
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis (2005) 1.19
Calcitonin. Curr Med Chem (1999) 1.18
Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials (2004) 1.16
Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology (1997) 1.16
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res (2000) 1.16
Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcif Tissue Int (1985) 1.14
Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int (2012) 1.11
Distal biceps tendon anatomy: a cadaveric study. J Bone Joint Surg Am (2007) 1.11
Isolation and preliminary characterization of temperature-sensitive mutants of Sindbis virus strain AR339. J Gen Virol (1974) 1.08
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis (2001) 1.07
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br (2001) 1.07
Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines. Cancer Res (1980) 1.06
Osteoarthrosis of the facet joints resulting from anular rim lesions in sheep lumbar discs. Spine (Phila Pa 1976) (1999) 1.05
Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells. Bone (2000) 1.05
Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol (1997) 1.04
The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol (2010) 1.01
Demyelination in mice resulting from infection with a mutant of Semliki Forest virus. Acta Neuropathol (1981) 1.01
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone (2002) 1.01
Virulence of temperature-sensitive mutants of Sindbis virus in neonatal mice. Infect Immun (1979) 1.00
Isolation and preliminary characterization of Semliki Forest virus mutants with altered virulence. J Gen Virol (1980) 0.98
Two mutations in the envelope glycoprotein E2 of Semliki Forest virus affecting the maturation and entry patterns of the virus alter pathogenicity for mice. Virology (1991) 0.98
Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone (2001) 0.97
Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. J Cell Physiol (1998) 0.97
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture. Cancer Res (1982) 0.97
The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res (2001) 0.97
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer (2003) 0.95
Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol (1985) 0.95
Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone (2008) 0.95
Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells. J Biol Chem (1989) 0.95
Some bacteriophages active against Rhizobium trifolii strain W19. J Virol (1973) 0.94
Regulation of osteoclast activity in peri-implant tissues. Biomaterials (2004) 0.94
A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity. J Gen Virol (1994) 0.94
Surface changes in a strain of Rhizobium trifolii on mutation to bacteriophage resistance. J Gen Microbiol (1972) 0.94
Relationship between serum RANKL and RANKL in bone. Osteoporos Int (2011) 0.94
Regulation of the synthesis of Sindbis virus-specified RNA: role of the virion core protein. J Gen Virol (1978) 0.92
The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol (1998) 0.92
Opposing influences of glucocorticoid and retinoic acid on transcriptional control in preosteoblasts. Mol Endocrinol (1989) 0.92
The avirulent A7 Strain of Semliki Forest virus has reduced cytopathogenicity for neuroblastoma cells compared to the virulent L10 strain. J Gen Virol (1983) 0.92
Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone (2003) 0.91
Calcitonin receptors in a cloned human breast cancer cell line (MCF 7). Biochem Biophys Res Commun (1980) 0.90
Calcitonin receptor isoforms in mouse and rat osteoclasts. J Bone Miner Res (1995) 0.90
Calcitonin binding and degradation by two cultured human breast cancer cell lines (MCF 7 and T 47D). Biochem J (1981) 0.89
Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T 47D). J Biol Chem (1981) 0.89
Mechanisms of calcitonin induction of prolonged activation of adenylate cyclase in human cancer cells. J Cyclic Nucleotide Protein Phosphor Res (1983) 0.89
The effect of infection with Sindbis virus and its temperature-sensitive mutants on cellular protein and DNA synthesis. Virology (1976) 0.89
Covalent cross-linking of a photoactive derivative of calcitonin to human breast cancer cell receptors. J Biol Chem (1982) 0.89
The midline posterior elbow incision. An anatomical appraisal. J Bone Joint Surg Br (1995) 0.88
Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer (1997) 0.88
The induction of interferon by temperature-sensitive mutants of Sindbis virus: its relationship to double-stranded RNA synthesis and cytopathic effect. J Gen Virol (1976) 0.88
Effect of alphavirus infection on mouse embryos. Infect Immun (1982) 0.87
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol (1999) 0.87
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther (2006) 0.87
Retinoic acid modulation of mRNA levels in malignant, nontransformed, and immortalized osteoblasts. J Bone Miner Res (1991) 0.87
Type I collagen influence on gene expression in UMR106-06 osteoblast-like cells is inhibited by genistein. J Endocrinol (1998) 0.86
Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: paired studies of pre- and post-shunted subjects. Gut (1979) 0.86
Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrinol (1995) 0.86
Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther (2005) 0.86
Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J Bone Miner Res (2000) 0.85
Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther (2005) 0.85
Multiplication of virulent and demyelinating Semliki Forest virus in the mouse central nervous system: consequences in BALB/c and SJL mice. J Gen Virol (1990) 0.85
Critical molecular regulators, histomorphometric indices and their correlations in the trabecular bone in primary hip osteoarthritis. Osteoarthritis Cartilage (2010) 0.85
Sigmoid notch osteoplasty for chronic volar instability of the distal radioulnar joint: a case report. J Hand Surg Am (2001) 0.85
Novel action of retinoic acid. Stabilization of newly synthesized alkaline phosphatase transcripts. J Biol Chem (1994) 0.85
Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone (2000) 0.84
p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol (2001) 0.84
Identification of brain isoforms of the rat calcitonin receptor. Mol Endocrinol (1993) 0.84
Nature and biologic activity of "extrapancreatic glucagon": studies in pancreatectomized cats. Metabolism (1978) 0.84
Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01). Calcif Tissue Int (1986) 0.83
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol (2000) 0.83
Changes in osteocyte density correspond with changes in osteoblast and osteoclast activity in an osteoporotic sheep model. Osteoporos Int (2011) 0.83
A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine (2001) 0.83
The pathogenicity of the M9 mutant of Semliki Forest virus in immune-compromised mice. J Gen Virol (1984) 0.83
Sequence analysis of the avirulent, demyelinating A7 strain of Semliki Forest virus. J Gen Virol (1997) 0.83
Relationship between internalization and calcitonin-induced receptor loss in T 47D cells. Endocrinology (1984) 0.83
Regulation of membrane-associated tyrosine phosphatases in UMR 106.06 osteoblast-like cells. Biochem J (1995) 0.82
Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology (1994) 0.82